Curis Earnings Call Transcripts
Fiscal Year 2026
-
Updated data show emavusertib plus ibrutinib achieves high response rates in both BTKI-naive and BTKI-experienced PCNSL patients, exceeding historical controls. Regulatory discussions support accelerated approval, and expansion into CLL and other NHL subtypes is underway.
-
Stockholders approved both a reverse stock split and the option to adjourn the meeting if needed. No questions were raised, and final results will be filed in a Form 8-K within four business days.
-
The meeting covered five key proposals, including director elections, executive compensation, auditor ratification, and an increase in authorized shares, all of which were approved by majority vote. Voting procedures and risks related to forward-looking statements were also addressed.
-
Advanced registrational and proof-of-concept studies in PCNSL and CLL, with steady enrollment and promising early data. Net loss increased due to PIPE financing, but cash runway extends into 2027, contingent on warrant exercises.
-
Four key proposals—including increasing authorized shares, approving stock conversions and warrants, and adopting a new incentive plan—were presented and all passed by majority vote. Final results will be filed in a Form 8-K.
Fiscal Year 2025
-
Q4 2025 saw a swing to net income due to a one-time gain from the Erivedge sale, with R&D and G&A expenses down year-over-year. PCNSL and CLL studies are prioritized, with initial CLL data expected at ASH 2026 and operations funded into H2 2027.
-
Steady progress in lymphoma, CLL, and AML studies with promising early data and regulatory engagement. Net loss narrowed year-over-year, expenses declined, and cash runway extends into 2026, though additional capital will be sought before year-end.
-
Emavusertib, a first-in-class IRAK4 inhibitor, shows strong proof-of-concept in PCNSL and AML, outperforming standard therapies and offering a favorable safety profile. Expansion into CLL, other NHL subtypes, and solid tumors is planned, with pivotal studies and new data expected soon.
-
The company is advancing a pivotal IRAK4/FLT3 inhibitor in PCNSL with strong early efficacy, aiming for accelerated approval and planning a confirmatory trial. Expansion into CLL and AML is underway, with a focus on combination therapies to improve response rates and enable time-limited treatment.
-
Emavusertib clinical programs advanced across PCNSL, CLL, AML, and MDS, with strong engagement from KOLs and promising early efficacy data. Net loss and expenses declined year-over-year, and recent financing extends the cash runway into Q1 2026.
-
Q1 2025 saw improved financials, strong clinical progress in PCNSL and AML, and the addition of Dr. Hamdy as CMO. Emavusertib showed promising efficacy, and cash runway extends into Q4 2025.
-
The IRAK4 program is advancing in PCNSL with a pivotal trial enrolling 30-40 more patients over 12-18 months, supported by strong mechanistic rationale and early efficacy signals. Expansion to other NHL indications and AML is planned, with key data updates expected at major conferences.
Fiscal Year 2024
-
Strong clinical progress in NHL and AML, with emavusertib showing robust efficacy and receiving orphan drug status. Financial position improved with reduced losses and extended cash runway into Q4 2025 after recent equity offerings.
-
Emavusertib demonstrated promising early efficacy in PCNSL and AML, with regulatory discussions ongoing for accelerated approval. Net loss narrowed year-over-year, and recent financing extends cash runway into mid-2025. Key data updates are expected at ASH in December.
-
IRAK4-targeted therapies are advancing in AML and NHL, with proof-of-concept data sets expanding and regulatory discussions ongoing. Early results in FLT3-mutated AML and primary CNS lymphoma are promising, and pivotal trial alignment with FDA is expected by year-end.
-
Emavusertib, a novel IRAK4 inhibitor, is showing promising safety and efficacy in NHL and AML, with a 50% response rate in relapsed/refractory PCNSL and durable activity in FLT3-mutated AML. Expansion into solid tumors and key clinical milestones are supported by a strong cash position.
-
Emavusertib showed promising early efficacy in both PCNSL and AML, with regulatory discussions advancing in the US and Europe. Net loss narrowed slightly year-over-year, and cash is expected to fund operations into Q1 2025. Initial data from key studies are anticipated by year-end.